Baltimore, MD (October 10, 2013) – Venable LLP helps Takeda defeat product liability claims relating to Takeda’s diabetes medication Actos®.
After a four-week jury trial in the case of An v. Takeda Pharmaceutical Company, a circuit court judge entered judgment in favor of Takeda, marking Takeda’s second win defending Actos.
Venable LLP’s Bruce R. Parker and Craig A. Thompson served as co-counsel for Takeda. Also representing Takeda was H. Douglas Wabner of Norton Rose Fulbright.
At trial, Takeda presented evidence that it acted responsibly in researching and developing Actos and in monitoring the medicine since it has been on the market, and that Actos is a safe and effective medication as described in the product labeling that was properly designed and did not cause the plaintiff's bladder cancer.
This is the second case regarding Actos to go to trial, with Takeda triumphing in both of them. The first case, Cooper v. Takeda Pharmaceutical Company, was tried in Los Angeles in April, and resulted in a judgment for Takeda after the court determined that the opinion of the plaintiff’s specific causation expert was inadmissible. Bruce Parker of Venable was also co-lead counsel in that case for Takeda.
Note: Venable is an American Lawyer Global 100 law firm serving clients globally. Headquartered in Washington, DC, with offices in California, Delaware, Maryland, New York and Virginia, Venable LLP lawyers and legislative advisors serve the needs of our domestic and global clients in all areas of corporate and business law, complex litigation, intellectual property, regulatory, and government affairs around the globe.